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A B S T R A C TObjective: The objective of this study was to assess the total annual
economic burden of melanoma and kidney, prostate, and ovarian
cancers in Russia using the uniﬁed methods. Methods: The general
prevalence-based cost-of-illness model was developed to evaluate the
annual health and social care costs and value of lost productivity
attributable to the following cancers: melanoma and kidney, prostate,
and ovarian cancers from the perspective of the overall governmental
budget. All costs were calculated using the “bottom-up” costing
technique for the total population of patients with studied cancer,
including both newly diagnosed patients stratiﬁed by cancer stage
and patients diagnosed in previous years who were still alive in the
study year. Results: The lowest aggregate annual cost was found for
melanoma—€17.48 million (52.4% health care costs, 34.9% social care
costs, 12.7% attributed to productivity loss) and the highest—€84.52
million—for prostate cancer (72.0%, 19.0%, and 9.0%, respectively).ee front matter Copyright & 2014, International S
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ndence to: Victoria I. Ignatyeva, The Russian Presid
d Economics, Center for Health Techonology AssEstimations for kidney and ovarian cancers were €45.33 and €45.56
million, respectively, with a similar distribution (42.5%–45.2% health
care costs, 39.0%–40.3% social care costs, 14.5%–18.5% lost productiv-
ity). Cost for a newly diagnosed patient was several times higher than
for a patient diagnosed in previous years (€1144– €1947 vs. €145–€417,
respectively). For patients in the ﬁrst year after diagnosis, the major
part of economic burden was attributed to health care costs, whereas
for those diagnosed before the study year, costs not related to health
were more prominent, except for prostate cancer. Conclusions: The
economic impact of cancers is more prominent during the ﬁrst year
after diagnosis. A considerable part of the economic burden of cancer
lies outside the health sector.
Keywords: cancer, cost-of-illness, economic burden, health care costs
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
According to federal statistics, by the end of 2012 there were
almost 3 million cancer patients registered in Russia, approxi-
mately 2% of the total population. Cancer is the second leading
cause of disability and mortality. More than 280,000 people die
because of cancer every year in Russia, almost one third of them
being younger than 60 years [1].
Despite the growing understanding of the magnitude of
economic burden caused by cancer, data on its actual size in
Russia are sparse and there is no uniﬁed methodology for
accurate estimation. Few cost studies of speciﬁc types of cancer
in Russia have been conducted; all of them used inconsistent
methods and sources of information, especially for the assign-
ment of unit costs or prices for the identiﬁed resource consump-
tion [2–4]. This could be explained by difﬁculties in data collection
resulting from the speciﬁcs of the federal surveillance system and
health care ﬁnancing in Russia [5,6]. Such discrepancies in
research methods and data make comparison or combination
of research ﬁndings almost impossible. Consequently, it hindersthe process of health technology assessment, vitally important
for rational decision making under the conditions of limited
resources.
The objective of this study was to estimate the economic
burden of melanoma and kidney, prostate, and ovarian cancers
from the perspective of the government’s overall budget using
the developed standard methodology. These cancers were
chosen to test the developed cost-of-illness model for several
reasons. First, we were looking for diseases considered to be a
public health problem with different epidemiologic and clinical
characteristics to observe their effect on the results. Second, we
expected our ﬁndings to be of use for health technology assess-
ment; therefore, we selected cancers for which there were new
treatments to enter the Russian market and no previous research
on their costs has been done.
Thus, we selected melanoma as one of the cancers with the
most rapidly growing incidence and with a similar impressive
increase in mortality—36.39% and 39.75%, respectively, during 10
years (from 1999 to 2009). Prostate cancer is one of the most
prevalent cancers among men (68.1 cases per 100,000) and is alsoociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Ovarian cancer is one of the leading cancers killing women of
working age. In 2009, almost 70% of ovarian cancers were
diagnosed at advanced stages; hence, more than one quarter of
the patients died during the ﬁrst year after diagnosis. Kidney
cancer was chosen as an example of cancer for which only
incidence data are collected on the federal level.Methods
Model Overview and Structure
We have developed a general prevalence-based cost-of-illness
model to evaluate the annual health care and social care costs
and value of lost productivity attributable to the following
cancers: melanoma (International Statistical Classiﬁcation of Dis-
eases, 10th Revision [ICD-10] code C43), kidney cancer (ICD-10 code
C64), prostate cancer (ICD-10 code C56), and ovarian cancer (ICD-
10 code C53). All costs were calculated using the “bottom-up”
costing technique for the total population of patients with
studied cancer, including both newly diagnosed patients strati-
ﬁed by cancer stage (i.e., localized, regional, distant, unstaged)
and patients diagnosed in previous years who were still alive in
2009 (the study year). The model was built using Microsoft Excel
2010 software.
Our cost-of-illness calculations were performed using differ-
ent data sources because detailed data sets containing all the
necessary information are rarely available to researchers in
Russia. When the parameters needed for calculations were not
found in the data collected and published by the federal stat-
istical services, we applied to regional registries, extrapolating
the derived evidence to the whole country. Data unavailable both
from federal and regional surveillance systems were extracted
from published studies. Finally, to derive details not found in
published sources, we held an expert survey of 21 participants
from eight Russian regions.
All statistical information and prices were taken for the year
2009 (study year), the latest available year for all statistical data at
the time the research was started. The national currency rubles
was converted into euros by using the mean nominal exchange
rate in 2009 [7].
Main rates and values used for cost calculations and their
sources are listed in Appendix 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2014.07.002.
Cancer Patient Populations
Incidence and prevalence data of studied cancers and distribu-
tion data of newly diagnosed cases by cancer stage were acquired
from federal health statistics collected for the whole country [8,9].
Age and sex distribution data of patients and stratum-speciﬁc
rates of cancer treatments were derived from six regional cancer
registries, in total covering 8.3% of the Russian population.
For kidney cancer, the federal surveillance system collects
only incidence data; therefore, we have estimated the total
number of patients in Russia on the basis of the number of
newly diagnosed patients from the federal data and the ratio of
the total number of patients to newly diagnosed patients from
regional cancer registries.
Estimates of the total annual social care cost and lost
productivity were based on the number of individuals employed
and permanently disabled because of cancer among the studied
patient populations. We have assumed that the age-speciﬁc rate
of employment for cancer patients at the time of diagnosis did
not differ from that for the general population; therefore, we have
used data from federal statistics [10–12]. Our estimation of thenumber of “potentially” employed persons included people of
postretirement age because the rate of employment among them
reaches 34.4% according to federal statistic surveillance.
The number of individuals permanently disabled because of
cancer was calculated as the product of the total number of
registered cases of disability due to cancer from federal statistics
and rates attributable to speciﬁc types of cancer from Russian
published research [13–16]. For persons newly registered as
permanently disabled in 2009, all related costs were calculated
for 6 months only.
Health Care Costs
Health care costs were estimated as the sum of payments made
to health care providers for inpatient (hospital stay) and out-
patient care (polyclinic/outpatient center visits and bed-days at
outpatient day-care centers) for different types of cancer treat-
ment and budget spending on the provision of medications to
cancer patients in outpatient care.
The general modeling approach to calculate the cost of
inpatient and outpatient care is presented in Table 1. Stratum-
speciﬁc estimation of health care resource utilization expressed
as the number of outpatient visits and inpatient days was
obtained through combining data from different sources—num-
ber of patients from federal statistics, rates of different types of
cancer treatments from regional cancer registries, and average
number of inpatient days and visits for each type of cancer
treatment studied through the expert survey. Average costs per
hospital and outpatient day care center bed-day and outpatient
visit costs were taken from the annual report of the Ministry of
Health on the provision of medical care to citizens in 2009 [17]. In
this report, all annual expenditures on medical care borne by
governmental and public medical insurance budgets are attrib-
uted to the total number of hospital and outpatient days and
outpatient visits provided by all medical institutions in the
Russian Federation, despite their specialization or afﬁliation.
Therefore, the average cost of amount of care derived from this
source represents all costs related to diagnostics and treatment
including laboratory testing, all types of manipulations, medica-
tions, and so forth.
According to federal and regional regulations, cancer patients
have a right for the provision of all medications in outpatient care
free of charge. The government covers all expenses. In our model,
we assessed these budget spendings on medications for the
whole country on the basis of data from four regional registries.
Social Care Costs
Social care costs were assessed as the budget spending on sick-
leave payments and disability pensions attributable to cancer.
Because there were no statistical data available on the
number of working days missed by cancer patients and experts
were unable to provide this information, we assumed the number
of working days missed because of temporary disability caused
by cancer to be equal to the number of inpatient days for
employed individuals. This restrictive approach was chosen to
avoid the overestimation of social costs. The average social
payment for one missed working day because of illness was
deﬁned on the basis of statistical data on the total expenses and
the number of sick-leave days paid in 2009 from the Social
Insurance Fund [18].
The size of the average disability pension was derived from
the Report of the Pension Fund for the year 2009 [17].
Value of Productivity Losses
Value of productivity losses was calculated as the amount of
gross domestic product (GDP) unproduced by the employed
Table 1 – Example of calculating annual resource consumption related to the provision of cancer treatment
(chemotherapy at stage III of cancer for newly diagnosed patients) using different sources of information.
Variable Melanoma Kidney
cancer
Prostate
cancer
Ovarian
cancer
Reference
1 Number of all newly diagnosed patients
in 2009 (Nnd)
7,578 17,053 25,215 12,034 Federal statistics [8,9]
2 % of stage III cancer among all newly
diagnosed (NndIII)
19 24.14 34.9 40.5 Federal statistics [8,9]
3 % starting cancer treatment among
newly diagnosed stage III patients (Ptr)
93.4 76.55 92 82 Regional cancer registries
4 Annual per-person rate of chemotherapy
(Rch)
0.2626 0.0282 0.14 1.06 Regional cancer registries
5 % undergoing chemotherapy in
outpatient clinic (Choutp)
0 50 100 0 Experts’ survey
6 Average annual number of outpatient
visits (V)
0 9 8 0 Experts’ survey
7 Total number of outpatient visits
provided because of chemotherapy
0 400 9068 0 Calculations (Nnd  NndIII 
Ptr  Rch  Choutp  V)
8 % undergoing chemotherapy at hospital
(Chinp)
100 50 0 100 Experts’ survey
9 Average hospital length of stay (LOS) (d) 21 21 0 22 Experts’ survey
10 Total number of hospital days due to
chemotherapy
7416 933 0 93199 Calculations (Nnd  NndIII 
Ptr  Rch  Chinp  LOS)
Note. Full list of rates and values used for the calculation of economic burden of studied cancers is provided in Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2014.07.002.
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rary or permanent disability associated with studied cancers.
Thus, the value of one missed working day was assumed to be
equal to the share of annual GDP produced by the employed
person during one working day.
To avoid overestimation of productivity losses, expressed as
the unproduced GDP, we followed principles of the friction cost
approach, assuming that productivity loss occurs only during the
period of time necessary to reestablish the initial production level
(i.e., the friction period) and workers leaving employment are
replaced by unemployed workers at an extremely low opportu-
nity cost. Because there are no statistical or research data for
Russia giving accurate estimate of the length of the friction
period, in our calculations of the lost productivity we took into
account only 10% of working days missed by cancer patients,
based on experts’ opinion.
Productivity losses associated with cancer mortality were not
estimated because of the lack of data and intention to avoid
double counting because there is a rather high probability that a
cancer patient is registered as a disabled person before death.
As mentioned earlier, the number of working days missed
because of temporary disability (i.e., time away from work to
undergo treatment or recover from associated adverse effects)
was assumed to be equal to the number of inpatient days. The
number of working days missed because of permanent disability
was assessed as half of the working days per year (we assumed
that the registration of disability cases is distributed equally
throughout the year) multiplied by the number of cancer patients
registered for the ﬁrst time in the study year as permanently
disabled and by the age-speciﬁc employment rate.
The productivity losses of unpaid caregivers were not
included in calculations because of the absence of data.Sensitivity Analysis
We conducted various one-way sensitivity analyses to determine
the sensitivity of results to key assumptions inherent in the
analysis. Because our health care cost estimations were based onan expert survey, we varied the amount of hospital days and
outpatient visits, as well as medication costs by 50%. Uncertainty
in the number of working days missed because of temporary
disability was accounted for by rerunning the analysis for
numbers increased and decreased by 50%. The rates of perma-
nent disability attributable to studied cancers were varied
upwards and downwards by 50%.Results
According to the federal surveillance data, there were 68,200
patients with melanoma, 95,900 women with ovarian cancer,
110,400 men with prostate cancer, and 17,000 new cases of kidney
cancer registered in Russia in 2009. On the basis of these data, we
modeled the patient populations for further estimation of cancer
costs (Table 2).
The lowest aggregate annual cost (€17.48 million) was found
for melanoma and the highest (€84.52 million) for prostate cancer
(Table 3). Table 4 provides estimates of the resource units’
consumption per 1000 registered patients.
Although in general the structure of the economic burden was
similar for all studied cancers, with health care costs constituting
the main part, results of cost estimation for prostate cancer were
markedly different. Health care costs accounted for more than
70% and loss of GDP for less than 10% of the total cost of illness
for prostate cancer, although for other studied cancers, these
shares were found to be 45% to 52% and 13% to 18%, respectively
(Table 3). This ﬁnding could be partly explained by the older age
of patients with prostate cancer—their mean age was 70 years at
the moment of diagnosis; for other studied cancers, this param-
eter varied between 58 and 61 years. Consequently, the rate of
employment was lower for this patient population. Also, we can
expect that there might be more individuals already registered by
social services as permanently disabled because of causes other
than cancer in this older population.
Almost 50% of the total annual cost was attributed to the
newly diagnosed patients, though they formed only 11% to 23% of
Table 2 – Patient populations in studied types of cancer (Russian Federation, 2009).
Type of cancer Total number of
patients registered*
Among all registered patients
Newly
diagnosed
Registered by social services
as permanently disabled†
Potentially
employed‡
Melanoma (С 43) 68,161 7,578 5,434 34,178
Kidney cancer (С64) 96,893 17,053 17,132 46,242
Prostate cancer (С61) 110,430 25,215 14,582 36,451
Ovarian cancer (С53) 95,861 12,034 16,251 41,750
* Data collected by the federal surveillance system, except kidney cancer when the total number of registered patients was calculated by
authors on the basis of federal statistics and data from regional cancer registries.
† Calculated by authors on the basis of federal statistics and published research data.
‡ Calculated by authors on the basis of federal statistics and data from regional cancer registries.
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diagnosed patient started from €1144 for melanoma and reached
€1947 for prostate cancer. The average cost per patient diagnosed
in previous years was several times lower—€145 for melanoma
and €417 for prostate cancer.
Marked differences were also found in the structures of total
annual per patient costs depending on the time spent from the
diagnosis. For patients in the ﬁrst year after diagnosis, the major
part of economic burden was attributed to health care costs; for
those diagnosed before the study year, costs not related to health
were more prominent. The only exception was prostate cancer
probably due to the older age of the population, as explained
earlier (Table 5).
Costs for newly diagnosed patients depended on the stage of
disease at the diagnosis— distant stages were several times more
expensive than localized, excluding ovarian cancer. The excep-
tion might be explained by aggressive treatment with consec-
utive courses of chemotherapy provided to the patients with
ovarian cancer even at the early stage of disease (Table 6).
Several one-way sensitivity analyses were conducted to test
the robustness of our ﬁndings. First, we tested the effect of
varying costs of care and medications upwards and downwards
by 50%. It resulted in 6% to 27% changes in total cancer costs,
with results for prostate cancer being the most sensitive to
changes in medication costs and ovarian cancer for changes in
medical care costs. Varying the rates of permanent disability due
to the studied cancer by 50% produced a variation in total annual
cost by 12% to 27%, with results for prostate cancer being the
least sensitive. Changes by 50% in the proportion of missed
working days taken into account for the assessment of the GDPTable 3 – Annual costs of studied types of cancer in Russ
Cost Melanom
Total costs, € million 17.48
% of GDP of Russia in 2009 0.0020
Total health care costs, € million (% of total costs) 9.16 (52)
Inpatient and outpatient care costs, € million 4.46
% of total spending on medical care in Russia in 2009 0.0143
Medications costs, € million 4.70
Total social care costs, € million (% of total costs) 6.10 (35)
Sick-leave payments, € million 0.59
Disabiity pensions, € million 5.51
Total GDP loss, € million (% of total costs) 2.22 (13)
GDP lost because of temporary disability, € million 0.26
GDP lost because of permanent disability, € million 1.96
Notes. GDP in Russia in 2009—€86,219 billion [19]. Total spendings on me
GDP, gross domestic product.loss (used as a proxy measure for the friction period) resulted in
4% to 9% variation in total costs (Table 7).Discussion
This was the ﬁrst study to estimate the full economic burden,
including costs related and not related to health care, for several
cancers in Russia using uniﬁed methods and sources of informa-
tion. We estimated that the total annual cost of studied cancers
varied between €17.48 million and €84.52 million, more than 80%
of which was direct budget spending on health and social care.
We have demonstrated that the main part of costs is during
the ﬁrst year after diagnosis—the average costs per newly
diagnosed patient were several times higher than per patient
diagnosed in previous years. Health care costs constituted the
main part of burden during the ﬁrst year, varying from €1004
(melanoma) to €1946 (prostate cancer). For instance, the per
capita standard of health care ﬁnancing approved by government
in 2009 was €173 [20].
We have used conservative estimation of the cost of medical
care—average cost of hospital day or outpatient visit according to
statistics collected by the Ministry of Health. Although this
decision underestimated the care provided to cancer patients,
which could be much more expensive than the care provided to
the patient with other type of disease, it was the only available
option for the perspective of overall government budget and it
guaranteed the comparability of results of the study.
The estimated burden seems small compared with other
countries, mostly because of low public spending for health careia in 2009.
a Kidney cancer Prostate cancer Ovarian cancer
45.33 84.52 45.56
0.0053 0.0098 0.0053
20.48 (45) 60.88 (72) 19.35 (42)
8.72 15.52 14.09
0.0279 0.0497 0.0451
11.77 45.37 5.27
18.26 (40) 16.04 (19) 17.78 (39)
0.89 1.26 1.31
17.36 14.78 16.47
6.59 (15) 7.59 (9) 8.42 (18)
0.40 0.56 0.58
6.19 7.03 7.84
dical care in the Russian Federation in 2009—€3124 billion [17].
Table 4 – Resource units per 1000 registered patients with studied cancers in Russia in 2009.
Resource unit Melanoma Kidney Prostate cancer Ovarian cancer
Days in the hospital
Total 1,940.13 2,768.59 4,121.56 4,743.52
Surgery* 1,355.51 1,682.10 2,041.56 1,079.47
Immuno (hormone) therapy 0.00 29.57 0.00 0.00
Chemotherapy 544.49 96.97 27.02 3,300.34
Radiation therapy 27.07 194.80 1,161.73 256.62
Symptomatic (palliative) care 13.06 565.67 303.53 12.21
Diagnostics 0.00 199.48 587.71 94.89
Days in outpatient care
Total 92.97 0.00 320.18 0.00
Surgery 2.98 0.00 0.00 0.00
Chemotherapy 81.86 0.00 0.00 0.00
Radiation therapy 8.13 0.00 320.18 0.00
Outpatient visits
Total 2,084.24 2,433.22 4,542.99 2,626.21
Immuno (hormone) therapy 98.65 168.00 1 043.36 0.00
Chemotherapy 0.00 4.14 158.30 0.00
Radiation therapy 0.00 0.00 695.44 0.00
Symptomatic (palliative) care 119.51 322.57 357.29 70.30
Diagnostics 375.30 350.83 683.58 960.02
Follow-up 1,490.78 1,587.68 1,605.03 1,595.89
Number of persons registered as permanently disabled* 79.72 176.81 132.05 169.53
Number of sick-leave days (days of temporary disability) 1,049.90 1,115.25 1,383.28 1,655.24
Working days missed because of temporary disability 749.93 796.61 988.06 1,182.32
Working days missed because of permanent disability 5,598.36 12,465.04 12,424.07 15,951.31
Average budget spending on medication provision in outpatient
care (€)
68,910.00 121,460.00 410,831.63 54,930.00
GDP, gross domestic product.
* The separation of types of treatment was predetermined by coding in regional cancer registries.
† For persons registered as permanently disabled in 2009 for the ﬁrst time, all related costs were calculated only for 6 mo. Average cost of hos-
pital day in Russia in 2009—€28.42. Average cost of day in outpatient care in Russia in 2009—€7.33. Average cost of outpatient visit in Russia in
2009—€ 4.62. Payment per 1 day of temporary disability—€8.26. Social pension for disability, monthly—€108.02. Average amount of GDP pro-
duced by employed person during working day in Russia in 2009—€151.26.
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and the conservative approach we used to avoid overestimation
given the scarcity of available information. Still the observed
trends are similar.
Several researches have demonstrated that a considerable
part of costs is attributable to the ﬁrst year after diagnosis. So, in
European studies the costs in the ﬁrst year after diagnosis of
prostate cancer varied between €3,705 and €10,165 and costs for
5 years of disease were found to be between €8,158 and €12,794
[21]. Annualized mean net costs of initial care in the United
States were estimated to be $98,788 for ovarian cancer, $46,048
to $46,077 for kidney cancer, and $6,057 to $6,524 for melanoma,
and of continuing care were $8,296, $6,018 to $6,255 and $915 to
$1,951, respectively [22]. Changes in costs corresponding to the
cancer stage were also present in several studies. In US-based
studies, annual melanoma direct medical per patient costs were
rising from $992 to $31,032 for stages 0 to II to $34,103 to
$152,244 for stage IV [23]. The annual per patient health care
cost for the localized stage of renal cell carcinoma was found to
be lower than that for regional and higher than that for distant
and unstaged cancer—$36,968, $41,857, $26,573, and $19,693,
respectively [24].
Social care costs, such as sick-leave payments and disability
pensions, are not always included into estimations of the eco-
nomic burden of disease. Deﬁnitely they could not be treated as
costs when the researcher takes the societal perspective because
these are costs for the government and income for patients. Inour case, the initially taken governmental perspective justiﬁes
the inclusion of these costs. Also, social care costs are an
important argument often used by politicians and decision
makers in Russia.
Traditionally, lost labor productivity is measured in terms of
wages foregone of people who have died or become disabled, or
who have missed work for a period of time because of illness. In
our case, we followed the approach commonly used by Russian
researchers and estimated the loss of GDP. Thus, we achieved
results comparable with other Russian-based studies. The other
reason was the chosen perspective of the overall government
budget, which did not allow using the lost personal income as the
cost estimate.
Our study is subject to several limitations, with some of them
being common to all cost-of-illness analyses performed in Russia
and some speciﬁc for cancers [5]. Ideally, the cost-of-illness
estimations should be done on the basis of information coming
from the database linking epidemiologic, demographic, and
health care utilization data, as is done in the Surveillance,
Epidemiology, and End Results Program Medicare database, often
used for estimating cancer costs in the United States. Unfortu-
nately, we cannot expect to ﬁnd data of such quality in Russia at
the present time. Data needed for cancer cost estimation are
sparse; therefore, we had to collect and synthesize data from
different sources with their own limitations: ofﬁcial statistics
provide only a limited set of data, often only as an aggregated
result; information from the regional cancer registries might be
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Table 6 – Annual mean total cost (€) per patient
depending on the time of diagnosis and stage of
disease in Russia in 2009.
Group of
patients
Melanoma Kidney
cancer
Ovarian
cancer
Prostate
cancer
Diagnosed in
previous
years
145 285 296 416
Newly
diagnosed,
all stages
1144 1322 1724 1946
Local stage 801 930 1718 1067
Regional
stage
2007 1716 1791 2724
Distant stage 2137 1946 1794 2802
Unstaged 295 125 297 54
V A L U E I N H E A L T H R E G I O N A L I S S U E S 4 C ( 2 0 1 4 ) 5 8 – 6 5 63skewed because of different interpretation of registered events;
and experts’ opinion surveys are known for their deviations.
We have not studied the costs borne by cancer patients,
though there are limited data that they often have to pay
themselves for the medications and provided treatment [25].
There is no full-scale research on this issue in Russia because it
is very difﬁcult to collect data on it. Patients and physicians
reluctantly provide information on out-of-pocket payments
because according to the existing regulations all services should
be provided to cancer patients free of charge.
It is still necessary to mention that the cost-of-illness method
in itself implies using assumptions because it is impossible to
register and account for all costs in every detail. Most of the
assumptions in this study most likely lead to an underestimation
of the economic burden of cancers, resulting in minimal estima-
tion of associated costs.Conclusions
Our study provides the ﬁrst estimation of the economic
burden of melanoma and prostate, ovarian, and kidney
cancer in the Russian Federation. Almost 40% of the costs lie
outside the health sector, despite the small size of social
payments and conservative approach to productive losses
measurement.
Source of ﬁnancial support: These ﬁndings are the result of
work fulﬁlled in the frames of the project supported by the
Russian Presidential Academy of National Economy and Public
Administration.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/
j.vhri.2014.07.002: or, if a hard copy of article, at www.valuein
healthjournal.com/issues (select volume, issue, and article).
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novoobrazovaniya v Rossii v 2012 godu (zabolevayemost i smertnost).
Moscow: FGU «MNIOI im. P.A. Gertsena» Minzdrava Rossii; 2013.
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